Stocks to Watch: MEI Pharma, Hawaiian Electric Industries

Dow Jones10-26

By Connor Hart

MEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics. The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. Aardvark made an initial $500,000 cash payment and may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales. MEI Pharma shares rise 28%, to $3.50, in after-hours trading.

Hawaiian Electric Industries disclosed that Ken Griffin's hedge-fund firm Citadel, and related funds, purchased a stake in the company. Citadel Advisors, Citadel Advisors Holdings and Citadel GP each own about 3.6 million shares of the utility's common stock, or about 2.2% of its total outstanding stock. Citadel Securities Group, Citadel Securities GP and Griffin also have stakes in the company. Shares rise 4.8%, to $10.22, in postmarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 25, 2024 18:28 ET (22:28 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478099387?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-26 06:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478099387","market":"other","top_or_hot":-1,"title":"Stocks to Watch: MEI Pharma, Hawaiian Electric Industries","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> inked a deal valued at up to $62 million with Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. Aardvark made an initial $500,000 cash payment and may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales. MEI Pharma shares rise 28%, to $3.50, in after-hours trading. \n</p>\n<p>\n  Hawaiian Electric Industries disclosed that Ken Griffin's hedge-fund firm Citadel, and related funds, purchased a stake in the company. Citadel Advisors, Citadel Advisors Holdings and Citadel GP each own about 3.6 million shares of the utility's common stock, or about 2.2% of its total outstanding stock. Citadel Securities Group, Citadel Securities GP and Griffin also have stakes in the company. Shares rise 4.8%, to $10.22, in postmarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 25, 2024 18:28 ET (22:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: MEI Pharma, Hawaiian Electric Industries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: MEI Pharma, Hawaiian Electric Industries\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-26 06:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\nMEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics. The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEI","symbol_name":"Methode Electronics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2478099387","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478099387","pubTimestamp":1729895280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics. The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. Aardvark made an initial $500,000 cash payment and may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales. MEI Pharma shares rise 28%, to $3.50, in after-hours trading.Hawaiian Electric Industries disclosed that Ken Griffin's hedge-fund firm Citadel, and related funds, purchased a stake in the company. Citadel Advisors, Citadel Advisors Holdings and Citadel GP each own about 3.6 million shares of the utility's common stock, or about 2.2% of its total outstanding stock. Citadel Securities Group, Citadel Securities GP and Griffin also have stakes in the company. Shares rise 4.8%, to $10.22, in postmarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MEI":"Methode Electronics Inc","MEIP":"MEI Pharma","BK4145":"电子制造服务","BK4139":"生物科技","BK4081":"电力公用事业","HE":"夏威夷电力"},"translate_title":"值得关注的股票：MEI Pharma、Hawaiian Electric Industries","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEI":1,"MEIP":1,"HE":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nMEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics. The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. Aardvark made an initial $500,000 cash payment and may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales. MEI Pharma shares rise 28%, to $3.50, in after-hours trading. \n\n\n  Hawaiian Electric Industries disclosed that Ken Griffin's hedge-fund firm Citadel, and related funds, purchased a stake in the company. Citadel Advisors, Citadel Advisors Holdings and Citadel GP each own about 3.6 million shares of the utility's common stock, or about 2.2% of its total outstanding stock. Citadel Securities Group, Citadel Securities GP and Griffin also have stakes in the company. Shares rise 4.8%, to $10.22, in postmarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 18:28 ET (22:28 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478099387"}